Preclinical studies of dacomitinib showed potent activity against cancer cells harboring EGFR mutations and provided insight into its pharmacodynamics, indicating a longer duration of receptor downregulation compared to the first-generation TKIs [41]. The gene discussed is EGFR; the disease is cancer.